41.047 articles found

Advances in the management of depression in Parkinson's disease: A narrative review on vortioxetine, hyperbaric oxygen, and physical activity.

Mesquita I, Araújo B, Soares-Guedes C, Teixeira C, Caridade-Silva R, Summavielle T, Pinto L, Domingos J, Godinho C, Teixeira FG.

Biomed Pharmacother · 2026-09-28

DOI: 10.1016/j.biopha.2026.119954PMID: 42805007

Oral Environment and Aspiration Pneumonia Risk in Parkinson's Disease: A Narrative Review and Conceptual Framework.

Furuya H, Longnecker D, Almazan E, Hinojosa O, Rochester T, Carnaby G.

J Oral Rehabil · 2026-09-28

DOI: 10.1111/joor.70326PMID: 42805786

Continuous infusion therapy after deep brain stimulation in Parkinson's disease: indications, outcomes, and patient selection.

Hero M, Papić E, Grozdanić N, Vuletić V.

J Neural Transm (Vienna) · 2026-09-28

DOI: 10.1007/s00702-026-03300-2PMID: 42806146

Lifestyle medicine for neuroprotection: evidence and implementation in Asian contexts.

Kim S, Chung SJ, Yoon S, Bloem BR, Postma E, Kim R, Fujioka S, Nagaishi Y, Phokaewvarangkul O, Park KW, Tan EK, Khongprasert S, Youn J.

J Neural Transm (Vienna) · 2026-09-28

DOI: 10.1007/s00702-026-03294-xPMID: 42806148

Subthalamic nucleus beta oscillations and sleep disorders in Parkinson's disease: A new perspective on deep brain stimulation regulation mechanisms and circuits.

Huang H, Ruan P, Wang Y, Liu Z, Wu Y, Zhang Z, Jiang X, Fu P.

Parkinsonism Relat Disord · 2026-09-28

DOI: 10.1016/j.parkreldis.2026.109001PMID: 42844068

Ambroxol in Gaucher disease and GBA1-related Parkinson disease: an updated systematic review.

Lipiński P, Jezela-Stanek A, Tylki-Szymańska A.

Acta Neurol Belg · 2026-09-27

DOI: 10.1007/s13760-026-03202-wPMID: 42801449

Probing the Energy Landscape of α-Synuclein Amyloid Fibril Formation by Systematic K-to-Q Mutagenesis.

Kunka A, Farzadfard A, Larsen JA, Norrild RK, Saraceno F, Fricke C, Mohammad-Beigi H, Sadek A, Folke J, Aznar S, Buell AK.

Adv Sci (Weinh) · 2026-09-27

DOI: 10.1002/advs.77643PMID: 42801676

Short-term efficacy and safety of tavapadon for Parkinson's disease: An exploratory systematic review and meta-analysis of randomized clinical trials.

Campos TS, Pereira PS, Pires Marques ME, de Sousa Fernandes LR, Grassi Simões PR, Ribeiro TC, de Oliveira MPR, Andrade Nascimento Almeida M, Gonçalves OR, Nery GG, Andrade PGG.

Parkinsonism Relat Disord · 2026-09-27

DOI: 10.1016/j.parkreldis.2026.108995PMID: 42822261

Beyond bacteria: a multi-omics view of the gut–brain axis in Parkinson’s disease

Han H, Luo O, Li K, Rahaman S, Ok E, Zhang L, Liang M, Lin H.

Frontiers in cellular and infection microbiology · 2026-09-26

A review of FDG-PET biomarker analysis methods in Parkinson's disease.

Reimers E, Bevington C, Stoessl AJ, Sossi V.

J Parkinsons Dis · 2026-09-26

DOI: 10.1177/1877718x261492275PMID: 42798283

Mast Cells in Neuroimmune Interactions: Mechanisms, Pathophysiological Roles, and Therapeutic Implications.

Hasan A, Asfour AAR, Qaba H, Al-Sharabi AA, Asfoor A, Mohammed S, Al-Adhreai A, Güner S, ALSaeedy M.

Mol Neurobiol · 2026-09-26

DOI: 10.1007/s12035-026-06173-4PMID: 42799832

Insights into X-linked Dystonia-Parkinsonism and Spinocerebellar Ataxia type 36 Through the Lens of Amyotrophic Lateral Sclerosis/Frontotemporal Dementia.

Patel M, Das S, Kumari AP, Kumar A.

Mol Neurobiol · 2026-09-26

DOI: 10.1007/s12035-026-06209-9PMID: 42799858